Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Vitamin d study hopes to boost gut health in IBD patients

NCT ID NCT07177157

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 28 times

Summary

This study will give 150 adults with Crohn's disease or ulcerative colitis a daily 2000 IU vitamin D supplement for 12 months. Researchers want to see if patients stick with the supplement and whether it improves their quality of life. Participants will complete surveys, blood tests, and stool tests at the start, 6 months, and 12 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IBD-INFLAMMATORY BOWEL DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Victoria Hospital - London Health Sciences Centre

    London, Ontario, N6A 5A5, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Vitamin D3 (cholecalciferol) 2000 IU daily

What this could lead to

If successful, this could show that daily vitamin D is a simple, safe way to improve quality of life for people with inflammatory bowel disease.

What could go wrong

This is a small, early-phase study focused on adherence and blood levels, not on curing or controlling the disease itself. The results may not apply to all IBD patients.

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.